Akebia plunges 20% on muted Q1 print
Source: SeekingAlpha
2026-05-07 12:35:30 ET
More on Akebia
- Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day - Slideshow
- Akebia Therapeutics, Inc. (AKBA) Discusses Pipeline Progress and Strategic Focus on Kidney Disease Treatments at R&D Day Transcript
- Akebia Therapeutics, Inc. (AKBA) Presents at Leerink Global Healthcare Conference 2026 Transcript
- Akebia GAAP EPS of -$0.03 in-line, revenue of $53.5M beats by $1.83M
- Akebia Q1 2026 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Akebia plunges 20% on muted Q1 print
Akebia Therapeutics Inc.
NASDAQ: AKBA
AKBA Trading
-4.19% G/L:
$0.9458 Last:
857,459 Volume:
$0.9636 Open:
AKBA Latest News
May 28, 2026 08:00:00 am
Akebia Therapeutics to Present at the 2026 Jefferies Global Healthcare Conference
AKBA Stock Data
$399,375,819
257,405,013
0.93%
52
N/A
Biotechnology & Life Sciences
Healthcare
US
Cambridge
